• 1
    Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat New Biol 1971; 231: 232235.
  • 2
    Willis AL. An enzymatic mechanism for the antithrombotic and antihemostatic actions of aspirin. Science 1974; 183: 325327.
  • 3
    CLASP: a randomised trial of low-dose aspirin for the prevention and treatment of pre-eclampsia among 9364 pregnant women. CLASP (Collaborative Low-dose Aspirin Study in Pregnancy) Collaborative Group. Lancet 1994; 343: 619629.
  • 4
    ECPPA Collaborative Group. ECPPA: randomised trial of low dose aspirin for the prevention of maternal and fetal complications in high risk pregnant women. Br J Obstet Gynaecol 1996; 103: 3947.
  • 5
    Rotchell YE, Cruickshank JK, Gay MP, Griffiths J, Stewart A, Farrell B, Ayers S, Hennis A, Grant A, Duley L, Collins R. Barbados Low Dose Aspirin Study in Pregnancy (BLASP): a randomised trial for the prevention of pre-eclampsia and its complications. Br J Obstet Gynaecol 1998; 105: 286292.
  • 6
    Harrington K, Kurdi W, Aquilina J, England P, Campbell S. A prospective management study of slow-release aspirin in the palliation of uteroplacental insufficiency predicted by uterine artery Doppler at 20 weeks. Ultrasound Obstet Gynecol 2000; 15: 1318.
  • 7
    Yu CK, Papageorghiou AT, Parra M, Palma Dias R, Nicolaides KH; Fetal Medicine Foundation Second Trimester Screening Group. Randomized controlled trial using low-dose aspirin in the prevention of pre-eclampsia in women with abnormal uterine artery Doppler at 23 weeks' gestation. Ultrasound Obstet Gynecol 2003; 22: 233239.
  • 8
    Kurdi W, Campbell S, Aquilina J, England P, Harrington K. The role of color Doppler imaging of the uterine arteries at 20 weeks' gestation in stratifying antenatal care. Ultrasound Obstet Gynecol 1998; 12: 339345.
  • 9
    Albaiges G, Missfelder-Lobos H, Lees C, Parra M, Nicolaides KH. One-stage screening for pregnancy complications by color Doppler assessment of the uterine arteries at 23 weeks' gestation. Obstet Gynecol 2003; 96: 559564.
  • 10
    Papageorghiou AT, Yu CK, Bindra R, Pandis G, Nicolaides KH; Fetal Medicine Foundation Second Trimester Screening Group. Multicenter screening for pre-eclampsia and fetal growth restriction by transvaginal uterine artery Doppler at 23 weeks of gestation. Ultrasound Obstet Gynecol 2001; 18: 441449.
  • 11
    Morin L, Van den Hof MC; Diagnostic Imaging Committee, Society of Obtetricians and Gynaecologists of Canada. Ultrasound evaluation of first trimester pregnancy complications. J Obstet Gynaecol Can 2005; 27: 581591.
  • 12
    Meekins JW, Pijnenborg R, Hanssens M, McFadyen IR, van Asshe A. A study of placental bed spiral arteries and trophoblast invasion in normal and severe pre-eclamptic pregnancies. Br J Obstet Gynaecol 1994; 101: 669674.
  • 13
    Wang Y, Walsh SW, Kay HH. Placental lipid peroxides and thromboxane are increased and prostacyclin is decreased in women with pre-eclampsia. Am J Obstet Gynecol 1992; 167: 946949.
  • 14
    Vainio M, Kujansuu E, Iso-Mustajärvi M, Mäenpää J. Low dose acetylsalisylic acid in prevention of pregnancy-induced hypertension and intrauterine growth retardation in women with bilateral uterine artery notches. BJOG 2002; 109: 161167.
  • 15
    Ebrashy A, Ibrahim M, Marzook A, Yousef D. Usefulness of aspirin therapy in high-risk pregnant women with abnormal uterine artery Doppler ultrasound at 14–16 weeks pregnancy: randomized controlled clinical trial. Croat Med J 2005; 46: 826831.
  • 16
    Askie LM, Duley H, Henderson-Smart DJ, Stewart LA; PARIS Collaborative Group. Antiplatelet agents for prevention of pre-eclampsia: a meta-analysis of individual patient data. Lancet 2007; 369: 17911798.
  • 17
    American College of Obstetricians and Gynecologists. Hypertension in pregnancy. ACOG technical bulletin, no. 219. American College of Obstetricians and Gynecologists: Washington, DC, 1996.
  • 18
    Shevell T, Malone FD, Vidaver J, Porter TF, Luthy DA, Comstock CH, Hankins GD, Eddleman K, Dolan S, Dugoff L, Craigo S, Timor IE, Carr SR, Wolfe HM, Bianchi DW, D'Alton ME. Assisted reproductive technology and pregnancy outcome. Obstet Gynecol 2005; 106: 10391045.
  • 19
    Duley L, Henderson-Smart DJ, Meher S, King JF. Antiplatelet agents for preventing pre-eclampsia and its complications. Cochrane Database Syst Rev 2007; (2): CD004659.
  • 20
    Li DK, Liu L, Odouli R. Exposure to non-steroidal anti-inflammatory drugs during pregnancy and risk of miscarriage: population based cohort study. BMJ 2003; 327: 368.
  • 21
    Cerletti C, Dell'Elba G, Manarini S, Pecce R, Castelnuovo A, Scorpiglione N, Feliziani V, de Gaetano G. Pharmacokinetic and pharmacodynamic differences between two low dosages of aspirin may affect therapeutic outcomes. Clin Pharmacokinet 2003; 42: 10591070.
  • 22
    Vainio M, Mäenpää J, Riutta A, Ylitalo P, Ala-Fossi SL, Tuimala R. In the dose range of 0.5–2.0 mg/kg, acetylsalicylic acid does not affect prostacyclin production in hypertensive pregnancies. Acta Obstet Gynecol Scand 1999; 78: 8288.
  • 23
    Viinikka L, Hartikainen-Sorri AL, Lumme R, Hiilesmaa V, Ylikorkala O. Low dose aspirin in hypertensive pregnant women: effect on pregnancy outcome and prostacyclin-thromboxane balance in mother and newborn. Br J Obstet Gynaecol 1993; 100: 809815.
  • 24
    WFUMB Symposium on Safety of Ultrasound in Medicine. Conclusions and recommendations on thermal and non-thermal mechanisms for biological effects of ultrasound. Kloster-Banz, Germany. 14–19 April, 1996. World Federation for Ultrasound in Medicine and Biology. Ultrasound Med Biol 1998; 24 (Suppl 1):i xvi, S1S58.
  • 25
    Chervenak FA, McCullough LB. Research on the fetus using Doppler ultrasound in the first trimester: guiding ethical considerations. Ultrasound Obstet Gynecol 1999; 14: 161.